# Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma

> **NCT04977375** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chirag G. Patil** · enrollment: 10 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Pembrolizumab
- **RADIATION:** Stereotactic Radiation Therapy
- **PROCEDURE:** Surgical Resection

## Key facts

- **NCT ID:** NCT04977375
- **Lead sponsor:** Chirag G. Patil
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-09
- **Primary completion:** 2025-12
- **Final completion:** 2026-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2025-09-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04977375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04977375, "Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT04977375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*